The FNP Review

The 4 Women's Health High-Yield Concepts Every FNP Student Must Master for Boards

Women's Health · 4 min read · August 10, 2026

Navigating Women's Health on the FNP Boards

Women's health is a massive pillar of both the AANP and ANCC family nurse practitioner certification exams. From routine cervical cancer screening to complex endocrine disorders like polycystic ovary syndrome (PCOS), board questions love to test your ability to translate clinical guidelines into safe patient care. Let us break down four high-yield areas that frequently appear on the exam so you can walk into your test center feeling prepared and completely in control.

1. Cervical Cancer Screening Guidelines Demystified

Confused by cervical cancer screening intervals? You are not alone. This is one of the most heavily tested topics in FNP board history, and the questions are designed to see if you know the exact age cutoffs and co-testing intervals.

  • Ages 21 to 29: Cytology (Pap smear) alone every 3 years. HPV testing is not recommended as a primary screening tool in this age group because transient HPV infections are extremely common and often clear on their own.
  • Ages 30 to 65: Three options are acceptable: cytology alone every 3 years, high-risk HPV (hrHPV) co-testing every 5 years, or hrHPV primary testing every 5 years.
  • Ages 65 and older: Screening can cease if the patient has adequate negative prior screening (e.g., 3 consecutive negative Pap tests or 2 consecutive negative co-tests within the past 10 years, with the most recent test performed within the last 5 years).

Board Tip: If a patient has a history of cervical intraepithelial neoplasia grade 2 or higher (CIN 2+), they must continue routine surveillance for at least 25 years after spontaneous regression or surgical treatment, even if that extends past age 65.

2. Contraception Contraindications: Safety First

Board questions love safety scenarios, particularly involving combined hormonal contraceptives (CHCs) containing estrogen and progestin. You must instantly recognize when estrogen is strictly contraindicated using the U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC).

Never prescribe estrogen-containing methods to patients with:

  • A history of migraine with aura (due to significantly increased risk of ischemic stroke).
  • Active deep vein thrombosis (DVT) or pulmonary embolism (PE).
  • A history of breast cancer or current ischemic heart disease.
  • Hypertension that is poorly controlled or has vascular disease (if blood pressure is $\ge$ 160/100 mmHg, avoid CHCs).
  • Smokers aged 35 or older who smoke 15 or more cigarettes a day.

Clinical Pearl: For patients with contraindications to estrogen—such as postpartum smokers, those with migraines with aura, or a history of blood clots—progestin-only pills (mini-pills), the levonorgestrel IUD, or the depot medroxyprogesterone acetate injection are safe, highly effective alternatives.

3. Demystifying Polycystic Ovary Syndrome (PCOS)

PCOS is a classic endocrine disorder characterized by chronic anovulation and hyperandrogenism. To diagnose PCOS using the Rotterdam criteria, a patient must meet at least two of the following three features:

  1. Androgen excess (clinical signs like hirsutism, acne, or biochemical elevation of serum testosterone).
  2. Ovulatory dysfunction (oligomenorrhea or amenorrhea).
  3. Polycystic ovaries on pelvic ultrasound.

First-line treatment depends on the patient's immediate goals. If the patient desires pregnancy, ovulation induction with letrozole or clomiphene is indicated. If pregnancy is not desired, combined oral contraceptives are the gold standard to regulate menses and protect the endometrium from unopposed estrogen, alongside lifestyle modifications for metabolic health.

Clinical Pearl: Always screen patients diagnosed with PCOS for impaired glucose tolerance and type 2 diabetes with a 2-hour oral glucose tolerance test or HbA1c, because insulin resistance is a core driver of the syndrome.

4. Managing Perimenopausal Vasomotor Symptoms

Vasomotor symptoms—hot flashes and night sweats—disrupt the lives of many perimenopausal and menopausal women. When choosing hormone replacement therapy (HRT), the golden rule is to evaluate the presence of a uterus.

  • Patients with a uterus: Must receive combination estrogen-progestin therapy. Giving estrogen alone to a woman with a uterus drastically increases her risk of endometrial hyperplasia and endometrial cancer due to unopposed estrogen proliferation.
  • Patients without a uterus (post-hysterectomy): Can safely receive systemic estrogen-only therapy, which carries no endometrial risk.

For women who have contraindications to systemic hormone therapy—such as a history of estrogen-dependent breast cancer or venous thromboembolism—non-hormonal options like low-dose selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), such as paroxetine or venlafaxine, can provide meaningful relief.

You Have Got This

Conquering women's health on your board exam is all about mastering safety guidelines, recognizing high-yield clinical presentations, and understanding the 'why' behind each treatment. Take it one concept at a time, trust your clinical instincts, and remember that every question brings you one step closer to your FNP cap and gown. You are fully capable of crushing this exam.